Lykos Therapeutics is a public benefit company focused on developing MDMA-assisted therapy for PTSD and related mental health care. In 2024 it announced a name change from MAPS Public Benefit Corporation after raising new investment and continued its push toward FDA approval and commercialization.
Otsuka Pharmaceutical said its U.S. subsidiary plans to acquire Transcend Therapeutics for $700 million, with up to $525 million more tied to sales milestones. The deal would add TSND-201, a methylone-based PTSD drug now moving into Phase 3 testing in the U.S.
Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.
Compass Pathways' COMP360 synthetic psilocybin met primary endpoints in Phase 3 trials for treatment-resistant depression, with the company planning to submit a new drug application in Q4 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06117306 |
MDMA-assisted Massed Prolonged Exposure for PTSD |
RECRUITING | PHASE3 |
| NCT05979844 |
MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD |
COMPLETED | PHASE3 |
| NCT05173831 |
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans |
WITHDRAWN | PHASE2 |
| NCT05147402 |
Food Effects on Bioavailability of MDMA in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT05066282 |
Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD |
COMPLETED | |
| NCT04968938 |
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD |
WITHDRAWN | PHASE2 |
| NCT04784143 |
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD |
TERMINATED | PHASE2 |
| NCT04714359 |
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD |
COMPLETED | PHASE3 |
| NCT04454684 |
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders |
WITHDRAWN | PHASE2 |
| NCT04438512 |
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD |
NO_LONGER_AVAILABLE |
